International journal of laboratory hematology · 2026
Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non-High-Risk and Nonaggressive Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Manish K, Sanjeev Yadav, Pandey Akshita, Rahman Khaliqur, Vijayran Mona, Kapoor Poorvi, Roy Sayan Sinha, Gupta Ruchi, Chandra Dinesh, Kumar Kaushal, Sharma Vineet, Kashyap Rajesh
Аннотация
INTRODUCTION: The myeloma patients with baseline normal/near-normal serum free light chain (SFLC) ratio have been reported to respond favorably to the treatment, unlike patients with extreme/abnormal SFLC ratio. We hypothesized that this normal SFLC ratio could serve as a biomarker for favorable cytogenetic and outcome profiles.
MATERIALS AND METHODS: The flow cytometric immunophenotyping (FCM-IPT) and interphase FISH analysis of marrow aspirate were performed as per recommended guidelines, in all the newly diagnosed patients of plasma cell proliferative disorders, enrolled during this prospective study. Patients were risk-stratified as per ISS, R-ISS, and R2-ISS criteria. The outcome evaluation, in patients treated with standard 3-/4-drugs induction, was done at least 3 months after initiation of therapy.
RESULTS: A total of 306 patients with plasma cell proliferative disorders were enrolled; myeloma patients were 240 (n_SFLC = 23/240, 9.6%) and (ab_SFLC = 217/240, 90.4%). IgG lambda M-protein was more significantly seen in (n_SFLC) patients. None of the patients in the (n_SFLC) group showed circulating blood plasma cells. The (n_SFLC) patients did not show the presence of TP53 gene deletion and relatively lacked other high-risk genetics. The outcome analysis showed that more patients in the (n_SFLC) group attained ≥ VGPR (88.9% vs. 65.4% of ab_SFLC).
CONCLUSION: Based on this, we infer that the patients with a normal SFLC ratio are enriched with non-high-risk features and behave less aggressively.
MATERIALS AND METHODS: The flow cytometric immunophenotyping (FCM-IPT) and interphase FISH analysis of marrow aspirate were performed as per recommended guidelines, in all the newly diagnosed patients of plasma cell proliferative disorders, enrolled during this prospective study. Patients were risk-stratified as per ISS, R-ISS, and R2-ISS criteria. The outcome evaluation, in patients treated with standard 3-/4-drugs induction, was done at least 3 months after initiation of therapy.
RESULTS: A total of 306 patients with plasma cell proliferative disorders were enrolled; myeloma patients were 240 (n_SFLC = 23/240, 9.6%) and (ab_SFLC = 217/240, 90.4%). IgG lambda M-protein was more significantly seen in (n_SFLC) patients. None of the patients in the (n_SFLC) group showed circulating blood plasma cells. The (n_SFLC) patients did not show the presence of TP53 gene deletion and relatively lacked other high-risk genetics. The outcome analysis showed that more patients in the (n_SFLC) group attained ≥ VGPR (88.9% vs. 65.4% of ab_SFLC).
CONCLUSION: Based on this, we infer that the patients with a normal SFLC ratio are enriched with non-high-risk features and behave less aggressively.